Decision Resources, Inc., Dec 2005, Pages: 9
Opportunities and Challenges in the Japanese Market for CancerTherapies For the past 25 years, cancer has been the leading cause of death in Japan, and cancer mortality in that country has grown
Decision Resources, Inc., Dec 2009, Pages: 34
Biomarker and Diagnostic Opportunities Associated with Targeted CancerTherapies The influence of biomarkers in oncology has extended to just about every aspect of the drug-diagnostic relationship
BioPharm Reports (VennBio Ltd.), Jan 2011, Pages: 195
cancer (name of biomarker, potential opportunity, Response, reference)
Table 5.1 Biomarkers associated with response to therapy in breast cancer(name of biomarker, Drug, Response, breast cancer type
Expert Reviews Ltd, May 2011, Pages: 202
replacement therapy and breast cancer
Usha Salagame, Karen Canfell, Emily Banks
- Lactogens and estrogens in breast cancer chemoresistance
Gila Idelman, et al
- Src kinase: a therapeutic opportunity
Decision Resources, Inc., Dec 2009, Pages: 34
The Targeted CancerTherapies Pipeline: A Strategic Review The current flurry of research into the development of new drugs against novel cancer targets is unprecedented. Many pharmaceutical
Timely Data Resources, Inc., July 2011, Pages: 21
Disease and Therapy Review: Breast Cancer The Breast Cancer Disease and Therapy Review provides an overview of the disease and related conditions, with incidence, prevalence and mortality numbers
Datamonitor, Aug 2010 Cancer Targeted Therapies and Immunotherapies Market Forecast The oncology market has witnessed a sizeable shift of focus away from cytotoxic therapies and antihormonal therapies towards the more
Frost & Sullivan, Oct 2010, Pages: 69
regimes, there are several different types of support therapies that can be used for treatment. This situation is opening up considerable growth opportunities for cancer support therapies.
“Heightened
Decision Resources, Inc., Dec 2009, Pages: 38
pharma company opportunities—in the targeted cancertherapies market? What
do physicians believe can be done to reach the goal of adding years to a cancer patient’s life at a good quality of existence
Bioseeker, Oct 2010, Pages: 659
in Preclinical- and Phase II development.
- Protein and gene therapy are the dominating compound strategies of cancer vaccine drugs, which represent half of the entire pipeline. Cell therapy based cancer vaccines
Bioseeker, July 2011, Pages: 1323
represent almost 80% of the entire pipeline. Cell therapy based lung cancer drugs has the lowest representation in the defined target strategy portfolio compared to that of other compound strategies of lung
BioPharm Reports (VennBio Ltd.), Oct 2011, Pages: 60
stage and metastasis and other areas
Table 3: Current and emerging developments relating to blood biomarkers in colorectal cancer, relevant to opportunities. These include new opportunities relating
BioPharm Reports (VennBio Ltd.), Oct 2011, Pages: 60
. These include new opportunities relating to blood biomarkers in non-small cell lung cancer, including companies and organisations, advances in diagnostic performance, therapy indications, selection of patient
Bioseeker, Nov 2010, Pages: 777
Cancer Vaccines Drugs
Table 44: Pursued Target Strategies of Nucleic Acid Based Cancer Vaccines Drugs
Table 45: Potential Forms of Cell Therapy
Table 46: Vectors in Gene Therapy
Table 47: Overview
Arrowhead Publishers, Nov 2009
-cell lung cancer (SCLC) patients unsuitable for surgical resection, drug therapy plays a vital role in the management of lung cancer. Such high level of unmet need ensures the lung cancer
MP Advisors, March 2012, Pages: 60
targeted by Para-IV filer. The products selected span across four therapy areas
- Cardiovascular
- Cancer
- Central Nervous System
- Metabolic Disorders
Bioseeker, March 2012, Pages: 1103
Pancreatic Cancer Drugs
Table 46: Potential Forms of Cell Therapy
Table 47: Vectors in Gene Therapy
Table 48: Overview of the Competitive Landscape of Cell Therapy Based Pancreatic Cancer Drugs
Table
BioPharm Reports (VennBio Ltd.), Feb 2011, Pages: 95
therapies, including 22 therapeutic vaccines and 11 antibodies. Of the 22 vaccines in development, 7 (32%) are at clinical phases II – III.
Drugs used to treat breast cancer fall into three main groups
The Assessment Group, Jan 2011, Pages: 59
of progressive triple negative metastatic breast cancer
Figure 3.11 Changing therapy to manage neuropathy
Figure 3.12 Recommended treatment of progressive triple negative metastatic breast cancer with BRCA-1
Decision Resources, Inc., March 2010, Pages: 32
Licensing Opportunities: Cancer Vaccines Is high-risk development of therapeutic cancer vaccines a good opportunity for pharmaceutical companies? In 2009, excitement built around several late-stage
